|Icariside II induces apoptosis in U937 acute myeloid leukemia cells: role of inactivation of STAT3-related signaling.|
|Jump to Full Text|
|PMID: 22493659 Owner: NLM Status: MEDLINE|
|BACKGROUND: The aim of this study is to determine anti-cancer effect of Icariside II purified from the root of Epimedium koreanum Nakai on human acute myeloid leukemia (AML) cell line U937.
METHODOLOGY/PRINCIPAL FINDINGS: Icariside II blocked the growth U937 cells in a dose- and time-dependent manner. In this anti-proliferation process, this herb compound rendered the cells susceptible to apoptosis, manifested by enhanced accumulation of sub-G1 cell population and increased the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells. Icariside II was able to activate caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) in a time-dependent manner. Concurrently, the anti-apoptotic proteins, such as bcl-x(L) and survivin in U937 cells, were downregulated by Icariside II. In addition, Icariside II could inhibit STAT3 phosphorylation and function and subsequently suppress the activation of Janus activated kinase 2 (JAK2), the upstream activators of STAT3, in a dose- and time-dependent manner. Icariside II also enhanced the expression of protein tyrosine phosphatase (PTP) SH2 domain-containing phosphatase (SHP)-1, and the addition of sodium pervanadate (a PTP inhibitor) prevented Icariside II-induced apoptosis as well as STAT3 inactivation in STAT3 positive U937 cells. Furthermore, silencing SHP-1 using its specific siRNA significantly blocked STAT3 inactivation and apoptosis induced by Icariside II in U937 cells.
CONCLUSIONS/SIGNIFICANCE: Our results demonstrated that via targeting STAT3-related signaling, Icariside II sensitizes U937 cells to apoptosis and perhaps serves as a potent chemotherapeutic agent for AML.
|Sang-Hun Kang; Soo-Jin Jeong; Sun-Hee Kim; Ji-Hyun Kim; Ji Hoon Jung; Wonil Koh; Jung Hyo Kim; Dae Keun Kim; Chang-Yan Chen; Sung-Hoon Kim|
Related Documents :
|22289339 - Why do we not find polyps in the lungs? bronchial mucosa as a model in the treatment of...
17281659 - Visual modeling and simulation of adaptive immune system.
22861359 - Lymph node dissection--understanding the immunological function of lymph nodes.
22720239 - Trial watch: chemotherapy with immunogenic cell death inducers.
22443549 - Natural alternatives to in-feed antibiotics in pig production: can immunomodulators pla...
20686829 - Does dehydroepiandrosterone influence the expression of urticaria?-a mini review.
22162829 - Evolutionary genetic dissection of human interferons.
9058779 - Characterization of b cells expressing recombination activating genes in germinal cente...
19502589 - Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-04-06|
|Title: PloS one Volume: 7 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2012|
|Created Date: 2012-04-11 Completed Date: 2012-09-04 Revised Date: 2013-06-26|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e28706 Citation Subset: IM|
|College of Oriental Medicine, Kyung Hee University, Seoul, South Korea.|
|APA/MLA Format Download EndNote Download BibTex|
Antineoplastic Agents, Phytogenic
isolation & purification,
Apoptosis / drug effects
Caspase 3 / genetics, metabolism
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Dose-Response Relationship, Drug
Epimedium / chemistry*
Flavonoids / isolation & purification, pharmacology*
Gene Expression Regulation, Neoplastic / drug effects
Inhibitor of Apoptosis Proteins / antagonists & inhibitors, genetics
Janus Kinase 2 / antagonists & inhibitors, genetics
Leukemia, Myeloid, Acute / drug therapy*, pathology
Plant Extracts / chemistry
Plant Roots / chemistry*
Poly(ADP-ribose) Polymerases / metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 6 / genetics, metabolism
STAT3 Transcription Factor / antagonists & inhibitors*, genetics
Signal Transduction / drug effects, genetics
bcl-X Protein / antagonists & inhibitors, genetics
|0/Antineoplastic Agents, Phytogenic; 0/BCL2L1 protein, human; 0/BIRC5 protein, human; 0/Flavonoids; 0/Inhibitor of Apoptosis Proteins; 0/Plant Extracts; 0/STAT3 Transcription Factor; 0/STAT3 protein, human; 0/bcl-X Protein; 0/icarisid II; EC 188.8.131.52/Poly(ADP-ribose) Polymerases; EC 184.108.40.206/JAK2 protein, human; EC 220.127.116.11/Janus Kinase 2; EC 18.104.22.168/PTPN6 protein, human; EC 22.214.171.124/Protein Tyrosine Phosphatase, Non-Receptor Type 6; EC 3.4.22.-/Caspase 3|
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Publisher: Public Library of Science, San Francisco, USA
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Received Day: 18 Month: 4 Year: 2011
Accepted Day: 14 Month: 11 Year: 2011
collection publication date: Year: 2012
Electronic publication date: Day: 6 Month: 4 Year: 2012
Volume: 7 Issue: 4
E-location ID: e28706
PubMed Id: 22493659
Publisher Id: PONE-D-11-07002
|Icariside II Induces Apoptosis in U937 Acute Myeloid Leukemia Cells: Role of Inactivation of STAT3-Related Signaling Alternate Title:Role of STAT3 in Icariside II-Induced Apoptosis|
|Ji Hoon Jung1|
|Jung Hyo Kim3|
|Dae Keun Kim4|
|Kevin D. Buntingedit1||
1College of Oriental Medicine, Kyung Hee University, Seoul, South Korea
2Basic Herbal Research Group, Korea Institute of Oriental Medicine, Daejeon, South Korea
3Chosun Nursing College, Kwangju, South Korea
4College of Pharmacy, Woosuk University, Wanju, South Korea
5Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
|Emory University, United States of America
|Correspondence: * E-mail: firstname.lastname@example.org
Contributed by footnote: Conceived and designed the experiments: S. H. Kang SJJ Sung-Hoon Kim. Analyzed the data: S. H. Kang SJJ Jung Hyo Kim Sung-Hoon Kim. Wrote the paper: SJJ CYC Sung-Hoon Kim. Cell cycle analysis, TUNEL assay, Western blotting, siRNA transfection, and RT-PCR experiments: S. H. Kang Sun-Hee Kim JHJ. EMSA: WK. Cytotoxicity assay: Ji-Hyun Kim. Isolation of Icariside II: DKK.
Icariside II, a flavonoid compound, is derived from the stems and leaves of Epimedium koreanum that has been traditionally utilized for neurasthenia, amnesia and impotence in Oriental medicine , . The other compounds from E. koreanum exerted various biological activities. For instance, icariin could stimulate angiogenesis by activating the extracellular signal-related kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT/endothelial nitric oxide synthase (eNOS)-dependent signal pathways in human endothelial cells . Also, ikarisoside A inhibited osteoclatogenic differentiation via c-Jun N-terminal kinase (JNK) and nuclear factor kappa B (NF-κB) in RAW 264.7 cells . We and others recently reported that Icariside II appeared to possess anti-cancer activity against multiple myeloma , prostate cancer  and osteosarcoma cells .
Acute myeloid leukemia (AML) is an aggressive malignancy characterized by the rapid growth of abnormal white blood cells (WBCs). AML is primarily treated by chemotherapy and rarely applied by radiotherapy . Although various chemotherapeutic agents such as cytarabine, daunorubicin and idarubicin have been developed for AML treatment, they can affect even normal cells to cause unpleasant side effects such as anemia, bleeding and infection. In recent studies, many groups have suggested the potential of natural products as potent chemotherapeutic drugs for AML to improve the therapeutic efficacy and lower the side effects. For instance, wogonin, an active compound in Scutellaria baicalensis, induced apoptosis by inhibiting telomerase activity in HL-60 AML cells  and ajoene, a natural garlic compound, was suggested as an anti-leukemic agent for AML therapy . In addition, corchorusin-D, a saikosaponin-like compound isolated from Corchorus acutangulus, targeted mitochondrial apoptotic pathways in HL-60 and U937 cells .
In the present study, the underlying anti-cancer mechanisms of Icariside II in U937 AML cells were investigated using cytotoxicity assay, cell cycle analysis, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, Western blotting and electrophoretic mobility shift assay (EMSA).
Icariside II, a flavonoid compound, is purified from the stems and leaves of Epimedium koreanum (Fig. 1A). To evaluate the effect of this herb compound on the proliferation of U937 cells, MTT assay was performed. U937 cells were treated with Icariside II at the concentrations of 0, 25 or 50 µM for 0, 24, 48 or 72 h, respectively. The treatment with Icariside II dramatically inhibited the proliferation of U937 cells in a dose- and time-dependent manner (Fig. 1B).
To examine whether Icariside II could induce apoptosis in U937 cells, sub-G1 DNA contents were measured by DNA fragmentation analysis. Icariside II increased the accumulation of sub-G1 population to 10.14%, compared that of the control (1.1%) at 24 h after the treatment (Fig. 2A). TUNEL assay further confirmed the occurrence of apoptosis after U937 cells were treated with Icariside that increased the number of fluorescein isothiocyanate (FITC)-stained, TUNEL positive cells in a time-dependent manner (Fig. 2B).
Caspase-3 is a key mediator of apoptosis . Icariside II strongly blocked the expression of pro caspase-3 and induced cleavage of PARP, a substrate for caspase-3, in a time-dependent manner (Fig. 3A). Icariside II also mediated PARP cleavage in another AML cell line HL-60 (Fig. 3B), confirming the ability of Icariside II to induce apoptosis in AML cells. In addition, Icariside II treatment attenuated the expression levels of anti-apoptotic proteins including bcl-2, bcl-xL, survivin and COX-2 in a time-dependent manner inU937 cells (Fig. 3C).
We recently reported that Icariside II had the inhibitory effect on STAT3 activation in multiple myeloma cells . To test the effect of Icariside II on U937 cells, immunoblotting analysis was performed (Fig. 4A and B). The addition of Icariside II reduced the phosphorylation of STAT3 in a dose- and time-dependent manner in U937 cells. Inhibitory effect of Icariside II on STAT3 activation was also found in HL-60 cells (Fig. 4C). Consistently, EMSA assay revealed that this herb compound significantly inhibited the STAT3/DNA binding activity in a dose-dependent manner (Fig. 4D). In contrast, Icariside II did not show significant effect on the phosphorylation of STAT5 (Fig. 4E).
STAT3 is activated by cooperating with JAKs and/or directly by Src kinase . Here, we again demonstrated that the treatment with Icariside II decreased the level of phopsho-JAK2, but not phospho-JAK1 (data not shown), in a dose- and time-dependent manner (Figs. 5A and B). Furthermore, the addition of Icariside II blocked the phosphorylation of Src in a dose- and time-dependent manner (Figs. 5C and D), indicating that Icariside II inactivates STAT3 signaling pathway through inhibiting JAK2 and Src in U937 cells.
PTPs are known to induce dephosphorylation of protein tyrosine kinases (PTKs) including STAT family proteins  and the transient character of the tyrosine phosphorylation of JAK2 and STAT3 suggests the involvement of protein tyrosine phosphatases (PTPs) as negative regulators of this signaling pathway . To test whether protein tyrosine phosphatase (PTP) was involved in Icariside II-induced apoptosis in U937 cells, immunoblotting analysis was performed. The treatment with Icariside II increased the expression of SHP-1, an upstream PTP of JAK2, in a time-dependent manner (Fig. 6A). Consistently, Icariside II also enhanced mRNA level of SHP-1 in a time-dependent manner in U937 cells (Fig. 6B). Conversely, PTP inhibitor sodium pervanadate overturned the Icariside II-mediated inactivation of STAT3 in a dose-dependent manner (Fig. 6C). Interestingly, pervanadate treatment also reversed the cleavages of caspase-3 and PARP induced by Icariside II (Fig. 6D). Furthermore, silencing SHP-1 using its specific siRNA significantly blocked STAT3 inactivation and apoptosis induced by Icariside II (Fig. 6E), suggesting that Icariside II induced apoptosis via inhibition of STAT3 in U937 cells.
To further examine whether Icariside II specifically inhibits STAT3 signaling, we used STAT3 inactive MM.1S cells. The cells did not show any phosphorylation of STAT3 as well as STAT5 (Fig. 7A). Differently from STAT3 positive U937 cells, Icariside II treatment had no significant effect on phospho-JAK2 and SHP-1 expression in MM.1S cells (Fig. 7B), while Icariside II induced apoptosis by targeting bcl-2 and COX-2, but not bcl-xL and survivin (Fig. 7C).
In the current study, the underlying mechanisms of Icariside II-induced anti-cancer activity were investigated in U937 AML cells. Apoptosis is the process of programmed cell death characterized by a series of morphological alterations including plasma and nuclear membrane blebbing and cell shringkage , and the molecular regulation such as caspase activation . Here, we demonstrated that Icariside II significantly suppressed the viability of U937 cells, increased sub-G1 and TUNEL-positive cells and attenuated the expression of caspase-3, along with enhanced cleavage of PARP, indicating that Icariside II may exert its antitumor activity via enabling to induce apoptosis in U937 cells. Bcl-2 and inhibitor of apoptosis protein (IAP) family proteins are known as anti-apoptotic proteins , . We also showed that Icariside II attenuated the expression levels of bcl-2, bcl-xL and survivin in a time-dependent manner, further suggesting the Icariside II-induced apoptosis in U937 cells.
STAT3, one of member of the STAT family, is a transcriptional factor that can be activated by cytokines or growth factors in normal cellular responses. Recently, STAT3 has been considered as an important molecular target for cancer therapy due to its strong activation in various cancer cells including AML. Zhao and colleagues reported that sorafenib, a multikinase inhibitor, induced apoptosis in HL-60 AML cells by inhibiting Src kinase-mediated STAT3 phosphorylation . Redell and colleagues reported that a novel small molecule STAT3 inhibitor, C188-9, suppressed G-CSF-induced STAT3 phosphorylation and apoptosis induction in AML cells, implying that STAT3 inhibition can be a valuable strategy for targeted therapies for AML .
In this study, we found that Icariside II suppressed the phosphorylation of constitutively active STAT3 in AML cell lines U937 and HL-60. In contrast, Icariside II did not alter the phosphorylation of STAT5 in U937 cells, indicating the specificity of Icariside II for STAT3 in AML cells. Furthermore, Icariside II treatment dramatically inhibited the transcriptional activity of STAT3 in gel shift assay by disturbing the binding of STAT3/DNA in U937 cells, suggesting that constitutively active STAT3 activity was not promoted by Icarisde II to undergo a dephosphorylation event. Moreover, a significant reduction of phospho-JAK2 and Src, the upstream tyrosine kinases of STAT3, was observed in Icariside II-treated U937 cells in a dose- and time-dependent manner, which was similarly supported by our previous report in multiple myeloma cells . Thus, the anti-cancer activities of Icariside II can be exerted by its pleiotropic effects on the multiple targets including STAT3 as well as JAK2, Src, and anti-apoptotic bcl-2, bcl-xL, survivin and COX-2 in U937 cells.
Activation of tyrosine kinases including STAT3 is regulated by balancing with PTPs. Various PTPs have been reported to be responsible for dephosphorylation of STAT3, including SHP-1 , SHP-2 , T cell (TC)-PTP , phosphatase and tensin homolog (PTEN) , suppressor of cytokine signaling (SOCS)-1 . In our study, Icariside II treatment increased SHP-1 expression at protein and mRNA levels in U937 cells. Importantly, the co-treatment with pervanadate (a general PTP inhibitor) effectively blocked Icariside II-induced STAT3 inactivation as well as apoptosis, strongly indicating that Icariside II, via affecting SHP-1, had a negative effect on STAT3 for the induction of apoptosis in U937 cells. Similarly, STAT3 targeted efficacies were reported by potent natural compounds such as ursolic acid , guggulsterone , genipin  and compound K  in various cancer cells.
Of interest, Icariside II also induced apoptosis in STAT3 inactive MM.1S multiple myeloma cells. Nonetheless, Icariside II treatment did not target bcl-xL and survivin, and phosphorylation of JAK2 compared to STAT3 active U937 cells. Furthermore, highly expressed SHP-1 protein was not changed by Icariside II treatment in MM.1S cells. These results suggest Icariside II induced apoptosis through an alternative pathway in STAT3 inactive MM.1S cells.
In conclusion, Icariside II suppressed the growth of U937 cells, by sensitizing the cells to apoptosis, manifested by increasing TUNEL-positive cells and accumulation of sub-G1 population in U937 AML cells. Also, Icariside II treatment increased the expression caspase-3, cleavage of PARP, and decreased bcl-xL and survivin. In addition, suppressed the activation of STAT3 and JAK2 and enhanced SHP-1 expression in U937 cells. Moreover, blocking SHP-1 by sodium pervanate attenuated the Icariside II-induced STAT3 inhibition and PARP cleavage in U937 cells. These findings suggested that Icariside II can induce apoptosis via inactivation of STAT3-related signaling pathway in AML U937 cells.
U937, HL-60 and MM.1S cells were purchased from American Type Culture Collection (ATCC) (Rockville, MD) and maintained in RPMI 1640 containing antibiotic and antimycotic solution with 10% fetal bovine serum.
The anti-proliferative effect of Icariside II was determined by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Cells (5×103 cells/well) were seeded in a 96-well plate, and treated with Icariside II (0, 25 or 50 µM) for 0, 24, 48 or 72 h. The treated cells were incubated with medium containing 5 mg/ml of MTT for 2 h at 37°C and then solubilized by 200 µl of lysis solution. The absorbance was read on a microplate reader (Molecular Devices E-max) at 570 nm.
Cells were exposed to Icariside II (50 µM) for 0, 1 or 24 h and fixed in 70% cold ethanol overnight at −20°C. The fixed cells were centrifuged, washed, resuspended in 100 µl of PBS containing 10 µl of RNase A (10 mg/ml) and incubated for 1 h at 37°C, and stained by adding 900 µl of propidium iodie (PI) (50 µg/ml) for 30 min at room temperature in dark. The DNA contents of stained cells were analyzed using Cellquest Software with a FACSCalibur flow cytometry (BD Biosciences, San Jose, CA).
Individual apoptotic cell death was observed using DeadEnd™ fluorometric TUNEL assay kit (Promega, Madison, WI) as described by manufacturer. Cells were treated with 50 µM Icariside II for 0, 12 or 24 h and washed with cold PBS. The cells were fixed with 4% paraformaldehyde for 30 min, washed twice with PBS for 2 min, resuspended in permeabilization solution (0.1% Triton X-100 and 0.1% Sodium citrate) for 4°C overnight, and incubated with 25 µl of TUNEL assay mixture (Sigma, St. Louis, MO) for 60 min at 37°C in a humidified atmosphere in dark. After washing 3 times in PBS for 2 min and filtering, the cells were analyzed by the flow cytometry.
Whole-cell extracts were lysed in lysis buffer [20 mM tris (pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton X-100, 0.01 mg/ml aprotinin, 0.003 mg/ml leupeptin, 0.4 mM phenylmethylsulfonyl fluoride (PMSF), and 4 mM NaVO4]. Lysates were then spun at 13,000× g for 15 min to remove insoluble material and resolved on a 10% SDS gel. After electrophoresis, the proteins were electrotransferred to a nitrocellulose membrane, blocked with 5% nonfat milk, and probed with antibodies against caspase-3, PARP, bcl-2, bcl-xL, survivin, COX-2, SHP-1 (Santa Cruz Biotechnologies, Santa Cruz, CA), phospho-STAT3, STAT3, phospho-STAT5, STAT5, phospho-JAK2, JAK2, phospho-Src and Src (Cell Signaling, Danvers, MA) overnight. The blots were washed, exposed to horseradish peroxidase (HRP)-conjugated secondary antibodies for 2 h, and finally examined by enhanced chemiluminescence (ECL) (GE Health Care Bio-Sciences, Piscataway, NJ). Band intensities were quantified using NIH Image-J software.
The STAT3/DNA binding was analyzed by electrophoretic mobility shift assay (EMSA) using Gelshift Chemiluminescent EMSA kit (Active Motif, Carlsbad, CA). Nuclear extracts were prepared and incubated with STAT3 consensus oligonucleotides ([gene: 5′-GAT CCT TCT GGG AAT TCC TAG ATC-3′]) (Santa Cruz Biotechnologies, Santa Cruz, CA). The DNA/protein complex formed was separated from free oligonucleotides on 5% native polyacrylamide gels. Chemiluminescent detection was performed using ECL reagents according to the vendor's protocols (GE Health Care Bio-Sciences, Piscataway, NJ).
Total RNA was extracted by using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. cDNA was synthesized from 1 µg of total RNA and subjected to PCR reaction by using Superscript One Step reverse transcription-PCR (RT-PCR) kit (Invitrogen, Carlsbad, CA). The PCR conditions were 30 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 1 min. The primer sequences were as follows: shp-1 (forward primer [gene: 5′-AAT GCG TCC CAT ACT GGC CCG A-3′]; reverse primer [gene: 5′-CCC GCA GTT GGT CAC AGA GT-3′]) and gapdh (forward primer [gene: 5′-TCA CCA TCT TCC AGG AGC GA-3′]; reverse primer [gene: 5′-CAC AAT GCC GAA GTG GTG GT-3′]). PCR products were run on 2% agarose gel and then stained with ethidium bromide. Stained bands were visualized under UV light and photographed.
U937 cells were transiently transfected with STAT3-siRNA or control-siRNA (40 nM) (Santa Cruz Biotechnology, Santa Cruz, CA) for 48 h using INTERFERin™ transfection reagent (Polyplus-transfection Inc., New York, NY) according to manufacturer's protocols.
All data were expressed as means ± standard deviation (S.D.) of three independent experiments.
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (No. 2011-0063466). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
|1.||Kee CH. Year: 2000The pharmacology of Chinese herbs (2nd ed.)}.106107 CRC Press, Boca Raton, FL.|
|2.||Oh MH,Houghton PJ,Whang WK,Cho JH. Year: 2004Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity.Phytomedicine1154454815500267|
|3.||Chung BH,Kim JD,Kim CK,Kim JH,Won MH,et al. Year: 2008Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells.Biochem Biophys Res Commun37640440818789310|
|4.||Choi HJ,Park YR,Nepal M,Choi BY,Cho NP,et al. Year: 2010Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.Eur J Pharmacol636283520353769|
|5.||Kim SH,Ahn KS,Jeong SJ,Kwon TR,Jung JH,et al. Year: 2011Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.Eur J Pharmacol654101621172343|
|6.||Lee KS,Lee HJ,Ahn KS,Kim SH,Nam D,et al. Year: 2009Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells.Cancer Lett2809310019289254|
|7.||Choi HJ,Eun JS,Kim DK,Li RH,Shin TY,et al. Year: 2008Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells.Eur J Pharmacol579586517980359|
|8.||Bishop JF. Year: 1997The treatment of adult acute myeloid leukemia.Semin Oncol2457699045305|
|9.||Huang ST,Wang CY,Yang RC,Chu CJ,Wu HT,et al. Year: 2010Wogonin, an active compound in Scutellaria baicalensis, induces apoptosis and reduces telomerase activity in the HL-60 leukemia cells.Phytomedicine17475419577445|
|10.||Hassan HT. Year: 2004Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.Leuk Res2866767115158086|
|11.||Mallick S,Ghosh P,Samanta SK,Kinra S,Pal BC,et al. Year: 2010Corchorusin-D, a saikosaponin-like compound isolated from Corchorus acutangulus Lam., targets mitochondrial apoptotic pathways in leukemic cell lines (HL-60 and U937).Cancer Chemother Pharmacol6670971920033811|
|12.||Kothakota S,Azuma T,Reinhard C,Klippel A,Tang J,et al. Year: 1997Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis.Science2782942989323209|
|13.||Zhang Y,Turkson J,Carter-Su C,Smithgall T,Levitzki A,et al. Year: 2000Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity.J Biol Chem275249352494410823829|
|14.||Han Y,Amin HM,Franko B,Frantz C,Shi X,et al. Year: 2006Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.Blood1082796280316825495|
|15.||Lund IK,Hansen JA,Andersen HS,Moller NP,Billestrup N. Year: 2005Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling.J Mol Endocrinol3433935115821101|
|16.||Jacobson MD,Burne JF,Raff MC. Year: 1994Mechanisms of programmed cell death and Bcl-2 protection.Biochem Soc Trans226006027821645|
|17.||Thornberry NA,Lazebnik Y. Year: 1998Caspases: enemies within.Science281131213169721091|
|18.||Gao Z,Tian Y,Wang J,Yin Q,Wu H,et al. Year: 2007A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo.J Biol Chem282307183072717724022|
|19.||Zhao W,Zhang T,Qu B,Wu X,Zhu X,et al. Year: 2011Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.Anticancer Drugs22798820881478|
|20.||Redell MS,Ruiz MJ,Alonzo TA,Gerbing RB,Tweardy DJ. Year: 2011Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and apoptosis induction by a novel small molecule Stat3 inhibitor.Blood1175701570921447830|
|21.||Tenev T,Bohmer SA,Kaufmann R,Frese S,Bittorf T,et al. Year: 2000Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells.Eur J Cell Biol7926127110826494|
|22.||Kim H,Baumann H. Year: 1999Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.Mol Cell Biol195326533810409724|
|23.||Yamamoto T,Sekine Y,Kashima K,Kubota A,Sato N,et al. Year: 2002The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation.Biochem Biophys Res Commun29781181712359225|
|24.||Sun S,Steinberg BM. Year: 2002PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells.J Gen Virol831651165812075083|
|25.||Seki E,Kondo Y,Iimuro Y,Naka T,Son G,et al. Year: 2008Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings.J Hepatol4823724518068850|
|26.||Pathak AK,Bhutani M,Nair AS,Ahn KS,Chakraborty A,et al. Year: 2007Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells.Mol Cancer Res594395517855663|
|27.||Ahn KS,Sethi G,Sung B,Goel A,Ralhan R,et al. Year: 2008Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1.Cancer Res684406441518519703|
|28.||Lee JC,Ahn KS,Jeong SJ,Jung JH,Kwon TR,et al. Year: 2011Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.J Cell Biochem1121552156221344490|
|29.||Park S,Lee HJ,Jeong SJ,Song HS,Kim M,et al. Year: 2011Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.Food Chem Toxicol491367137221420464|
Previous Document: Uptake and accumulation of oxidized low-density lipoprotein during Mycobacterium tuberculosis infect...
Next Document: Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib b...